FiNews

Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M

Author: Landon Johnson

Eton Pharmaceuticals Chief Business Officer Sells Shares

David Krempa, Chief Business Officer of Eton Pharmaceuticals, filed a Form 4 reporting sales of company common stock. The transactions were executed at weighted-average prices ranging from approximately $31.47 to $33.88 per share.

Transaction Details

Five separate sales on May 22, 26, and 27, 2026 generated total proceeds of $3,229,923. After the sales, Krempa directly beneficially owns 25,249 shares of common stock.

The insider trading activity was reported to the SEC. Investors closely monitor executive stock transactions for insights into company performance.

Impacted Symbols

Symbols affected by this headline and their sentiment signals

ET
ETONNegative

Eton Pharmaceuticals, Inc.

A large insider sale by a top executive may signal reduced confidence in the company, potentially negatively impacting investor sentiment.

Impact score65%

The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.